A leading supplier of generic antiretroviral medicines has signed an agreement to manufacture new HIV medicines for sale in developing countries, the Medicines Patent Pool announced today.
The Indian company Emcure Pharmaceuticals “will be able to manufacture several products licensed to the Pool by Gilead Sciences, including: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the fixed-dose combination of these medicines known as the Quad (a combination of FTC, COBI, EVG and tenofovir),” the Patent Pool said.
“Generic manufacturers play a central role in providing low cost HIV medicines and have helped increase the number of people receiving treatment in the developing world, so the rapid uptake of our licences by generic companies is a positive sign,” Patent Pool Executive Director Ellen ‘t Hoen said in a statement.
Emcure, a top-15 Indian pharmaceutical company, is the third generic manufacturer to take licences from the Pool. Emcure sells in more than 76 countries around the world.
More information about the Medicines Patent Pool is available here.
